AML cells were allowed to engraft for several weeks and peripheral blood was periodically checked to determine the level of AML cells (human CD45+CD123+CD33+) as quantified by flow cytometry (Figure 3a). The gene discussed is PTPRC; the disease is acute myeloid leukemia.